[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
April 7, 2010

Researchers Focus on Contrast Safety

JAMA. 2010;303(13):1244. doi:10.1001/jama.303.13.1244

Chicago—Researchers have known for some time that the use of iodinated agents in contrast studies is associated with a risk of contrast-induced nephropathy (CIN) and that the risk is greater for those with compromised renal function. More recently, evidence has emerged that use of gadolinium-based agents is associated with a risk of another condition, nephrogenic systemic fibrosis (NSF), which has been reported only in persons with kidney disease.

Research presented at the Radiological Society of North America's annual meeting here in November reflects scientists' efforts to better understand these adverse effects and how to reduce the likelihood such problems will occur.

First Page Preview View Large
First page PDF preview
First page PDF preview